Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

BACKGROUND: Benign prostatic hyperplasia (BPH) refers to non‐malignant enlargement of the prostate gland that may cause bothersome lower urinary tract symptoms (LUTS). Alpha‐blockers (ABs) and 5‐alpha reductase inhibitors (5‐ARIs) are the mainstay of medical treatment. Recently, phosphodiesterase in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cochrane Database Syst Rev
Autors principals: Pattanaik, Smita, Mavuduru, Ravimohan S, Panda, Arabind, Mathew, Joseph L, Agarwal, Mayank M, Hwang, Eu Chang, Lyon, Jennifer A, Singh, Shrawan K, Mandal, Arup K
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2018
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517182/
https://ncbi.nlm.nih.gov/pubmed/30480763
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD010060.pub2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars